Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

176.72B

Market cap176.72B

Price-Earnings ratio

11.61

Price-Earnings ratio11.61

Dividend yield

3.04%

Dividend yield3.04%

Average volume

14.21M

Average volume14.21M

High today

$40.60

High today$40.60

Low today

$38.70

Low today$38.70

Open price

$40.13

Open price$40.13

Volume

25.12M

Volume25.12M

52 Week high

$81.44

52 Week high$81.44

52 Week low

$35.12

52 Week low$35.12

NVO News

Barron's 4h

Lilly and Novo Stocks Are Tumbling. How Amazon Is Shaking Up the GLP-1 Game.

Healthcare Lilly and Novo Stocks Are Tumbling. How Amazon Is Shaking Up the GLP-1 Game. In this article LLY NVO AMZN SPX Amazon announced a ‘GLP-1 Management Pr...

TipRanks 5h

Lilly, Novo slip after CVS opts out of Medicare obesity drug model

Shares of Eli Lilly (LLY) and Novo Nordisk (NVO) are under pressure on Tuesday after CVS Health (CVS) announced the company’s decision regarding Medicare obesit...

Investor's Business Daily 6h

Amazon Stock: Anthropic And OpenAI Deals Highlight 'Growing Confidence' In Custom AI Chips

Eli Lilly and Novo Nordisk's Newest Rival In Weight Loss? Amazon. 3:58 AM ET Shares of Eli Lilly, Novo Nordisk and Viking Therapeutics tumbled Tuesday after Am...

Analyst ratings

63%

of 35 ratings

Buy

31.4%

Hold

62.9%

Sell

5.7%

More NVO News

TipRanks 6h

Lexaria Bioscience provides update on GLP-1 oral pill market

Lexaria Bioscience (LEXX) provides an update of additional recent developments in the fast-moving glucagon-like peptide-1 oral market. The company said, ” The G...

Nasdaq 10h

A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly

Key Points Novo Nordisk and Eli Lilly are largely responsible for creating today's weight-loss drug market. The two companies, however, can’t fend off creativ...

Nasdaq 1d

Here's Why Agios Pharmaceuticals Crashed 23% Today

Key Points Agios Pharmaceuticals shares dropped 23% following Novo Nordisk's trial results. Novo's etavopivat outperformed Agios' mitapavit in key sickle cell...

Investor's Business Daily 1d

Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock

Technology Why Novo Nordisk's Surprise Win Hammered Agios Pharmaceuticals Stock Licensing Shares of Agios Pharmaceuticals (AGIO) took a header Monday after Novo...

TipRanks 1d

H.C. Wainwright cuts Agios target on smaller market post Novo data

H.C. Wainwright analyst Emily Bodnar lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $50 from $65 and keeps a Buy rating on the shares. Novo...

TipRanks 1d

Novo Nordisk Details Progress of DKK 15 Billion Share Buyback Programme

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 3d

Novo Nordisk’s Surprise Rebound: Value, Dividends and AI

Novo Nordisk ( (NVO) ) has risen by 7.45%. Read on to learn why. Claim 30% Off TipRanks Unlock hedge fund-level data and powerful investing tools for smarter, s...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.